SEATTLE, Feb. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the the BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 8:00 a.m. ET/2:00 p.m. CET in New York.
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe with respect to PIXUVRI® and a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.
CTI BioPharma Contacts:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-bio-ceo--investor-conference-300403774.html
SOURCE CTI BioPharma Corp.